98%
921
2 minutes
20
Introduction: Probiotic interventions in young livestock are gaining attention for their potential health benefits.
Methods: This study involved 15 weaned goat kids (2-3 months old; 10-15 kg body weight), including 10 healthy kids and 5 diarrheic kids. The kids were divided into three groups: Healthy Control (H, no treatment), Probiotic-Treated Healthy (T), and Diarrheic + Probiotic-Treated (D). All kids were maintained under standardized environmental conditions and fed a controlled diet (60% corn, 15% pea skin, 15% silage, 5% hay and 1% vitamin-mineral additives). Probiotic bacteria and were administered via oral gavage at a concentration of (1 × 10) CFU/mL for five consecutive days. Fecal samples were collected for sequencing of the bacterial 16S rRNA gene to analyze microbial composition.
Results: Healthy groups exhibited significantly greater species richness and diversity compared to the diarrheal group (p < 0.01). The predominant phyla identified were , , and .Increased levels of , , , and were noted in healthy treated kids, while UG_001 and decreased.
Discussion: The findings highlight significant gut microbiota differences between healthy and diarrheal kids, suggesting that modifications in gut microbiota composition could alleviate diarrhea, contributing to preventive and therapeutic strategies for this condition.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12213349 | PMC |
http://dx.doi.org/10.3389/fvets.2025.1604638 | DOI Listing |
Arq Gastroenterol
September 2025
The Japanese Society of Internal Medicine, Editorial Department, Tokyo, Japan.
Background: This study aims to analyze research trends and emerging insights into gut microbiota studies from 2015 to 2024 through bibliometric analysis techniques. By examining bibliographic data from the Web of Science (WoS) Core Collection, it seeks to identify key research topics, evolving themes, and significant shifts in gut microbiota research. The study employs co-occurrence analysis, principal component analysis (PCA), and burst detection analysis to uncover latent patterns and the development trajectory of this rapidly expanding field.
View Article and Find Full Text PDFJ Crohns Colitis
September 2025
Department of Gastroenterology, University Hospital of Marseille Nord, Assistance Publique-Hôpitaux de Marseille (AP-HM), Aix-Marseille University, Marseille, France.
Background And Aims: While this strategy is frequently used for other biologics, real-world evidence on subcutaneous (SC) vedolizumab (VDZ) dose intensification in inflammatory bowel disease (IBD) is lacking. This study aimed to assess the effectiveness and safety of SC VDZ intensification.
Methods: We conducted a retrospective study in 25 centers including all patients with active ulcerative colitis (UC) or Crohn's disease (CD) (defined by PRO2), and incomplete or loss of response to SC VDZ 108mg EOW when the drug was intensified.
Anesthesiology
September 2025
Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida.
Background: The brain-gut-microbiome (BGM) axis is a communication network through which the brain and gastrointestinal microbiota interact via neural, hormonal, immune, and gene expression mechanisms. Gut microbiota dysbiosis is thought to contribute to neurocognitive disorders, including perioperative neurocognitive disorder (PND), and to various metabolic abnormalities. Recently, we reported that sevoflurane induces neurocognitive deficits in exposed rats as well as their future offspring, with male offspring being particularly affected (intergenerational PND).
View Article and Find Full Text PDFInt J Surg
September 2025
Department of Cardiovascular Medicine, The Affiliated Panyu Central Hospital of Guangzhou Medical University (Cardiovascular Diseases Research Institute of Panyu District), Guangdong, China.
Curr Atheroscler Rep
September 2025
Division of Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center for Digestive Health, Houston Methodist Hospital, Houston, TX, USA.
Purpose Of Review: This review aims to characterize the known cardiovascular (CV) manifestations associated with inflammatory bowel disease (IBD) and the underlying mechanisms driving these associations.
Recent Findings: Gut dysbiosis, a hallmark of patients with IBD, can result in both local and systemic inflammation, thereby potentially increasing the risk of cardiovascular disease (CVD) in the IBD population. Micronutrient deficiencies, anemia, and sarcopenia independently increase the risk of CVD and are frequent comorbidities of patients with IBD.